Literature DB >> 27520411

High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.

Doreen Nguyen1, Diana Taheri1,2, Simeon Springer3,4, Morgan Cowan1, Gunes Guner1, Maria Angelica Mendoza Rodriguez1, Yuxuan Wang4, Isaac Kinde4, Christopher J VandenBussche1, Matthew T Olson1, Bernardo F P Ricardo1, Isabela Cunha5, Kazutoshi Fujita6, Dilek Ertoy7, Kenneth W Kinzler3,4, Trinity J Bivalacqua8, Nickolas Papadopoulos3,4, Bert Vogelstein3,4, George J Netto9,10,11.   

Abstract

Somatic activating mutations in the promoter of the telomerase reverse transcriptase (TERT) gene are the most common genetic alterations in urothelial carcinoma (UC) of the bladder and upper urinary tract. Little is known, however, about TERT-mutation status in the relatively uncommon but clinically aggressive micropapillary (MPC) variant. We evaluated the presence of TERT promoter mutations in MPC of the bladder and upper urinary tract. A retrospective search of our archives for MPC and UC with micropapillary features (2005-2014) was performed. All slides were reviewed to confirm the histologic diagnosis. Thirty-three specimens from 31 patients had FFPE blocks available for DNA analysis and were included in the study. Intratumoral areas of non-micropapillary histology were also evaluated when present. Samples were analyzed with Safe-SeqS, a sequencing error reduction technology, and sequenced using the Illumina MiSeq platform. TERT promoter mutations were detected in all specimens with pure MPC (18 of 18) and UC with focal micropapillary features (15 of 15). Similar to conventional UC, the predominant mutations identified occurred at positions -124 (C228T) (85 %) and -146 (C250T) (12 %) bp upstream of the TERT ATG start site. In heterogeneous tumors with focal variant histology, intratumoral concordant mutations were found in variant (MPC and non-MPC) and corresponding conventional UC. We found TERT promoter mutations, commonly found in conventional UC, to be frequently present in MPC. Our finding of concordant intratumoral mutational alterations in cases with focal variant histology lends support to the common oncogenesis origin of UC and its variant histology.

Entities:  

Keywords:  Micropapillary; Mutation; TERT; Telomerase reverse transcriptase; Urothelial carcinoma

Mesh:

Substances:

Year:  2016        PMID: 27520411      PMCID: PMC5561427          DOI: 10.1007/s00428-016-2001-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  30 in total

Review 1.  Molecular mechanisms of ETS transcription factor-mediated tumorigenesis.

Authors:  Adwitiya Kar; Arthur Gutierrez-Hartmann
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-09-25       Impact factor: 8.250

2.  TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.

Authors:  Isaac Kinde; Enrico Munari; Sheila F Faraj; Ralph H Hruban; Mark Schoenberg; Trinity Bivalacqua; Mohamad Allaf; Simeon Springer; Yuxuan Wang; Luis A Diaz; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; George J Netto
Journal:  Cancer Res       Date:  2013-10-11       Impact factor: 12.701

3.  Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer.

Authors:  Robert J A Bell; H Tomas Rube; Alex Kreig; Andrew Mancini; Shaun D Fouse; Raman P Nagarajan; Serah Choi; Chibo Hong; Daniel He; Melike Pekmezci; John K Wiencke; Margaret R Wrensch; Susan M Chang; Kyle M Walsh; Sua Myong; Jun S Song; Joseph F Costello
Journal:  Science       Date:  2015-05-14       Impact factor: 47.728

4.  Clinical outcome of patients with T1 micropapillary urothelial carcinoma of the bladder.

Authors:  Massimiliano Spaliviero; Guido Dalbagni; Bernard H Bochner; Bing Ying Poon; Hongying Huang; Hikmat A Al-Ahmadie; Timothy F Donahue; Jennifer M Taylor; Joshua J Meeks; Daniel D Sjoberg; S Machele Donat; Victor E Reuter; Harry W Herr
Journal:  J Urol       Date:  2014-03-03       Impact factor: 7.450

5.  Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation.

Authors:  Minghao Zhong; Wei Tian; Jian Zhuge; Xiaoyong Zheng; Tiangui Huang; Dongming Cai; David Zhang; Ximing J Yang; Pedram Argani; John T Fallon; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2015-01       Impact factor: 6.394

6.  Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists.

Authors:  Ankur R Sangoi; Andrew H Beck; Mahul B Amin; Liang Cheng; Jonathan I Epstein; Donna E Hansel; Kenneth A Iczkowski; Antonio Lopez-Beltran; Esther Oliva; Gladell P Paner; Victor E Reuter; Jae Y Ro; Rajal B Shah; Steven S Shen; Pheroze Tamboli; Jesse K McKenney
Journal:  Am J Surg Pathol       Date:  2010-09       Impact factor: 6.394

7.  Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer.

Authors:  Joshua J Meeks; Jennifer M Taylor; Kazuhito Matsushita; Harry W Herr; S Machele Donat; Bernard H Bochner; Guido Dalbagni
Journal:  BJU Int       Date:  2013-02-05       Impact factor: 5.588

Review 8.  Experimental models of histogenesis and tumor cell heterogeneity in bladder cancer.

Authors:  D Raghavan; P J Russell; J L Brown
Journal:  Semin Surg Oncol       Date:  1992 Sep-Oct

9.  Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.

Authors:  Isaac Kinde; Chetan Bettegowda; Yuxuan Wang; Jian Wu; Nishant Agrawal; Ie-Ming Shih; Robert Kurman; Fanny Dao; Douglas A Levine; Robert Giuntoli; Richard Roden; James R Eshleman; Jesus Paula Carvalho; Suely Kazue Nagahashi Marie; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Luis A Diaz
Journal:  Sci Transl Med       Date:  2013-01-09       Impact factor: 17.956

10.  Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients.

Authors:  Ashish M Kamat; Colin P N Dinney; Jason R Gee; H Barton Grossman; Arlene O Siefker-Radtke; Pheroze Tamboli; Michelle A Detry; Tracy L Robinson; Louis L Pisters
Journal:  Cancer       Date:  2007-07-01       Impact factor: 6.860

View more
  16 in total

1.  Evaluation of Sienna Cancer Diagnostics hTERT Antibody on 500 Consecutive Urinary Tract Specimens.

Authors:  Derek B Allison; Rajni Sharma; Morgan L Cowan; Christopher J VandenBussche
Journal:  Acta Cytol       Date:  2018-06-06       Impact factor: 2.319

2.  Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.

Authors:  Doreen N Palsgrove; Diana Taheri; Simeon U Springer; Morgan Cowan; Gunes Guner; Maria A Mendoza Rodriguez; Maria Del Carmen Rodriguez Pena; Yuxuan Wang; Isaac Kinde; Bernardo F P Ricardo; Isabela Cunha; Kazutoshi Fujita; Dilek Ertoy; Kenneth W Kinzler; Trinity J Bivalacqua; Nickolas Papadopoulos; Bert Vogelstein; George J Netto
Journal:  Hum Pathol       Date:  2018-11-14       Impact factor: 3.466

3.  TERT- beyond the territory: Usage of PCR-based TERT promoter assay in defining urothelial carcinoma in a case of long-standing prostatic adenocarcinoma.

Authors:  Rahul Mannan; Alexander S Taylor; Daniel E Spratt; Arul M Chinnaiyan; Jeffrey S Montgomery; Noah A Brown; Rohit Mehra
Journal:  Pathol Res Pract       Date:  2019-09-21       Impact factor: 3.250

4.  Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder.

Authors:  Maria Del Carmen Rodriguez Pena; Aline C Tregnago; Marie-Lisa Eich; Simeon Springer; Yuxuan Wang; Diana Taheri; Dilek Ertoy; Kazutoshi Fujita; Stephania M Bezerra; Isabela W Cunha; Maria Rosaria Raspollini; Lijia Yu; Trinity J Bivalacqua; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; George J Netto
Journal:  Virchows Arch       Date:  2017-06-08       Impact factor: 4.064

5.  Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma.

Authors:  Somak Roy; Dinesh Pradhan; Wayne L Ernst; Stephanie Mercurio; Yana Najjar; Rahul Parikh; Anil V Parwani; Reetesh K Pai; Rajiv Dhir; Marina N Nikiforova
Journal:  Mod Pathol       Date:  2017-05-26       Impact factor: 7.842

Review 6.  Variant Histology in Bladder Cancer-Current Understanding of Pathologic Subtypes.

Authors:  Manju Aron
Journal:  Curr Urol Rep       Date:  2019-11-28       Impact factor: 3.092

Review 7.  Toward urinary cell-free DNA-based treatment of urothelial carcinoma: a narrative review.

Authors:  Yujiro Hayashi; Kazutoshi Fujita
Journal:  Transl Androl Urol       Date:  2021-04

8.  Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma.

Authors:  Yujiro Hayashi; Kazutoshi Fujita; Kyosuke Matsuzaki; Makoto Matsushita; Norihiko Kawamura; Yoko Koh; Kosuke Nakano; Cong Wang; Yu Ishizuya; Yoshiyuki Yamamoto; Kentaro Jingushi; Taigo Kato; Atsunari Kawashima; Takeshi Ujike; Akira Nagahara; Motohide Uemura; Ryoichi Imamura; Tetsuya Takao; Shingo Takada; George J Netto; Norio Nonomura
Journal:  Cancer Sci       Date:  2019-04-07       Impact factor: 6.716

9.  Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy.

Authors:  Simeon U Springer; Chung-Hsin Chen; Maria Del Carmen Rodriguez Pena; Lu Li; Christopher Douville; Yuxuan Wang; Joshua David Cohen; Diana Taheri; Natalie Silliman; Joy Schaefer; Janine Ptak; Lisa Dobbyn; Maria Papoli; Isaac Kinde; Bahman Afsari; Aline C Tregnago; Stephania M Bezerra; Christopher VandenBussche; Kazutoshi Fujita; Dilek Ertoy; Isabela W Cunha; Lijia Yu; Trinity J Bivalacqua; Arthur P Grollman; Luis A Diaz; Rachel Karchin; Ludmila Danilova; Chao-Yuan Huang; Chia-Tung Shun; Robert J Turesky; Byeong Hwa Yun; Thomas A Rosenquist; Yeong-Shiau Pu; Ralph H Hruban; Cristian Tomasetti; Nickolas Papadopoulos; Ken W Kinzler; Bert Vogelstein; Kathleen G Dickman; George J Netto
Journal:  Elife       Date:  2018-03-20       Impact factor: 8.140

Review 10.  Telomere Maintenance Mechanisms in Cancer.

Authors:  Tiago Bordeira Gaspar; Ana Sá; José Manuel Lopes; Manuel Sobrinho-Simões; Paula Soares; João Vinagre
Journal:  Genes (Basel)       Date:  2018-05-03       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.